Skip to main content

Table 3 Clinical characteristics, resistance and molecular typing of CIP resistant or susceptibility-decreased H. influenzae strains

From: Microbial virulence, molecular epidemiology and pathogenic factors of fluoroquinolone-resistant Haemophilus influenzae infections in Guangzhou, China

No.

Age

Sex

Date

Department and infection

Causes and underlying diseases

Disk diffusion

E-test

Resistance

During previous 3 months

ST

QRDRs

Ci

L

Na

Ci

L

Hospitalization and antimicrobial

gyrA

parC

38

3

M

17.2.14

Respiratory RI, A

Contact with patient; rhinallergosis

28

25

6

0.38

0.38

AmCfCtST

N; Cf

12

Ser-84-Leu

–

254

70

M

16.5.16

Respiration (4), A

/; interstitial lung disease arthritis deformans

21

19

6

0.5

0.5

AmAsCfS

N; N

836

–

–

179

61

F

16.4.3

Gastrointestinal surgery, B

Radical mastectomy; mammary cancer cholecystolithiasis hypertension

19

21

–

1.5

0.75

CfST

Y; Cf

408

Ser-84-Leu

Ser-84-Ile

187

2

F

16.4.7

Pediatrics, A

Bronchoscopy; acleistocardia

20

6

–

1

0.5

CfS

Y (3); Cf

408

Ser-84-Leu

Ser-84-Ile

197

1

M

16.4.8

Pediatrics, A

Bronchoscopy; tracheostenosis, acleistocardia family history of rhinallergosis

19

23

–

1

0.75

CfS

Y (4); unspecified fluoroquinolone, Cf

408

Ser-84-Leu

Ser-84-Ile

216

62

M

16.4.21

Respiration (2), A

Catch cold, COPD, hypertension

20

21

–

0.5

0.5

AmAsAzS

Y; fluoroquinolone enoxacin, P

422

Ser-84-Leu

--

237

87

F

16.5.3

Respiration (3), A

Mechanical ventilation and catch cold; smoking COPD chronic corpulmonale

19

21

–

0.75

0.5

AmAsAzCfCtST

Y; N

422

Ser-84-Leu

-

291

61

M

16.7.12

Respiration (3), A

/; emphysema

20

6

–

0.75

0.5

AmAsAzCfST

N; N

408

Ser-84-Leu

Ser-84-Ile

387

56

M

16.10.10

Outpatient, A

Catch cold; /

6

18

–

> 12

3

M

/; N

1791

–

–

  1. Figures in brackets after department means different zones of the department. Figures in brackets of column Hospitalization means the frequency of hospitalization during previous 3 months
  2. M male, F female, / not mentioned, Y yes, N no, A community-acquired, B hospital-acquired, Am ampicillin, As ampicillin–sulbactam, Az azithromycin, Ci ciprofloxacin, Cf cefuroxime, Ct ceftriaxone, M meropenem, Na nalidixic acid, L levofloxacin, P piperacillin, S trimethoprim–sulfamethoxazole, T cefotaxime, QRDR quinolone resistance determining regions, ST sequence